Novo Nordisk Wegovy pill launches in Germany at $47.26

The launch comes as Germany becomes one of the first European markets to get the oral version of Wegovy, with Novo saying broader rollout across more than 30 markets is planned this year. But the equity market has not rewarded the news. Novo’s U.S.-listed shares were last around $47.26 on Aug. 7, only modestly above the recent low of $41.81 and well below the $61.72 peak seen in late January, underscoring how much faith has already been lost in the obesity story. The shares are also trading below their 200-day moving average, a sign the longer-term trend remains fragile even after a rebound from March’s trough.

For investors, the issue is not whether the drug class still has demand. It does. The question is whether Novo can convert that demand into durable, profitable growth in a market that has become more crowded, more price-sensitive and more politically exposed. Safety concerns around GLP-1 drugs, warnings from pharmacy groups about dubious online sales and continuing access problems have made the category harder to scale cleanly. High prices and uneven reimbursement also mean the fastest-growing patients are not always the most accessible ones.

The market’s hesitation is also shaped by the competitive backdrop. Lilly’s share price has held up far better, with the stock near $1,186, far above its 50-day moving average, suggesting investors see the U.S. rival as better positioned to capture the bulk of cardiometabolic growth. Lilly’s own filings show its incretin medicines already account for most revenue, reinforcing how dominant the category has become for the company. Novo, by contrast, is still fighting to convince the market that its obesity franchise can regain momentum after a sharp year of volatility.

Technically, Novo’s shares have improved from deeply oversold levels — the relative strength index has recovered to the low 40s from single digits in March — but the stock remains below its 50-day average, a sign traders have yet to fully buy into the rebound. That fits the broader narrative: the business is advancing, but confidence is rebuilding much more slowly than the product pipeline.

The next test is whether early European uptake and the upcoming broader rollout translate into prescriptions, reimbursement wins and stable supply. If they do, Novo may yet rebuild the case that the pill can extend its obesity lead beyond injections. If not, Germany will be remembered less as a launch pad than as another reminder that in obesity drugs, demand alone is no longer enough.